XML 35 R45.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements & Derivative Instruments - Additional Information (Detail) (USD $)
 6 Months Ended 1 Months Ended 6 Months Ended
Mar. 31, 2013
Jan. 25, 2013
Dec. 12, 2012
Sep. 30, 2012
Jun. 17, 2010
Mar. 31, 2013
Wisepower [Member]
Jan. 31, 2011
Unidym, Inc. [Member]
Mar. 31, 2013
Unidym, Inc. [Member]
Mar. 31, 2013
Ablaris Therapeutics, Inc. [Member]
Fair Value Measurements Disclosure [Line Items]                  
Non cash consideration received in sale of interest in subsidiary, bonds             $ 2,500,000    
Bond convertible conversion price per share             $ 2.00    
Derivative asset 30,011     280,261   0      
Loss from change in fair value of the derivative asset               250,250  
Warrants issued to acquire Common Stock   833,530 912,543   329,649        
Warrants outstanding 322,150                
Non-cash gain (loss) from change in fair value of the derivative liability 244,801               9,675
Duration of exchange rights 7 years                
Exchange right convertible conversion ratio for first year                 0.06
Exchange right convertible conversion ratio for second year                 0.04
Exchange right convertible conversion ratio for third year                 0.03
Exchange right convertible conversion ratio for fourth year                 0.02
Exchange right convertible conversion ratio for fifth year and beyond                 0.01
Number of exchange rights sold                 675,000
Contingent consideration $ 173,621     $ 173,621